Bifemelane (INN), sold under the brand namesAlnert andCeleport, is anantidepressant andcerebral activator that was widely used in the treatment ofcerebral infarction patients withdepressive symptoms in Japan, and in the treatment ofdementia as well.[1][2] It also appears to be useful in the treatment ofglaucoma.[3] It has been discontinued in Japan since 1998, when it was removed from the market reportedly for lack of effectiveness.[4]
^Koide S, Onishi H, Hashimoto H, Kai T, Katayama M, Yamagami S (1995). "Effects of bifemelane hydrochloride on plasma neuropeptide Y, 3-methoxy-4-hydroxyphenylethylene glycol and 5-hydroxy-indole acetic acid concentrations in patients with cerebral infarction".Drugs Under Experimental and Clinical Research.21 (5):175–80.PMID8846747.
^Shigemitsu T, Majima Y (1996). "Use of bifemelane hydrochloride in improving and maintaining the visual field of patients with glaucoma".Clinical Therapeutics.18 (1):106–13.doi:10.1016/S0149-2918(96)80183-4.PMID8851457.
^Naoi M, Nomura Y, Ishiki R, Suzuki H, Nagatsu T (January 1988). "4-(O-benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type A and B monoamine oxidase".Journal of Neurochemistry.50 (1):243–7.doi:10.1111/j.1471-4159.1988.tb13256.x.PMID3335842.S2CID35543291.
^Kovel'man IR, Tochilkin AI, Gorkin VZ (1991). "Structure and action of reversible monoamine oxidase inhibitors (review)".Pharmaceutical Chemistry Journal.25 (8):505–520.doi:10.1007/BF00777412.ISSN0091-150X.S2CID42477788.
^Dostert P (1994). "Can our knowledge of monoamine oxidase (MAO) help in the design of better MAO inhibitors?".Amine Oxidases: Function and Dysfunction. Vol. 41. pp. 269–279.doi:10.1007/978-3-7091-9324-2_35.ISBN978-3-211-82521-1.PMID7931236.For example, bifemelane [4-(O-benzylphenoxy)-N-methylbutylamine) is one of the few molecules in which both activities, reversible inhibition of MAO-A (Naoi et al., 1988) and inhibition of noradrenaline uptake (Egawa et al., 1983), although weak (IC50 = 10-6-10-7 M), coexist.{{cite book}}:|journal= ignored (help)
^Kondo Y, Ogawa N, Asanuma M, Matsuura K, Nishibayashi K, Iwata E (March 1996). "Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion".Neuroscience Research.24 (4):409–14.doi:10.1016/0168-0102(95)01017-3.PMID8861111.S2CID34313096.
^Moryl E, Danysz W, Quack G (June 1993). "Potential antidepressive properties of amantadine, memantine and bifemelane".Pharmacology & Toxicology.72 (6):394–7.doi:10.1111/j.1600-0773.1993.tb01351.x.PMID8361950.
N
Y (what is this?) (verify)